Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2
<p>In COVID-19, hypertension, diabetes mellitus, coronary artery disease, and immunosuppression are comorbid conditions most often associated with poor prognosis. Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers are widely used in the treatment of these diseases. T...
Bewaard in:
Hoofdauteur: | |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2020-07-02.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | peertech__10_17352_2455-2976_000138 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Didar Yanardag Acik |e author |
245 | 0 | 0 | |a Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2 |
260 | |b Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications, |c 2020-07-02. | ||
520 | |a <p>In COVID-19, hypertension, diabetes mellitus, coronary artery disease, and immunosuppression are comorbid conditions most often associated with poor prognosis. Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers are widely used in the treatment of these diseases. Therefore, scientists turned their attention to these drugs and brought up the question of whether angiotensin converting enzyme inhibitors and angiotensin receptor blockers may be drugs that adversely affect prognosis in SARS-CoV-2 infection. The authors generally discussed the role of these drugs in SARS-CoV-2 infection through the same mechanisms. We also investigated the effects of these drugs on the immune system.</p> | ||
540 | |a Copyright © Didar Yanardag Acik et al. | ||
546 | |a en | ||
655 | 7 | |a Review Article |2 local | |
856 | 4 | 1 | |u https://doi.org/10.17352/2455-2976.000138 |z Connect to this object online. |